Tuebingen

• This is a randomized, open-label, multi-center, global, Phase III study to assess the effectiveness and safety of two Immune Therapy drugs, … Ended recruitment
  2024-512212-21-00 5 2017-11-28 Advanced hepatocellular carcinoma (HCC)
• An Open label Study of Teclistamab in Subjects with Relapsed and Refractory Multiple Myeloma Ended recruitment
  2023-503438-40-00 7 2017-10-05 Relapsed/Refractory Multiple Myeloma
• International trial in Philadelphia chromosome-positive acute lymphoblastic leukemia Ended recruitment
  2024-515499-12-00 5 2017-10-02 Acute lymphoblastic leukemia
• „INSIGHT“ An explorative, open-labeled, phase I trial to evaluate feasibility and safety of eftilagimod alpha (IMP321, a LAG-3Ig fusion prot … Ended recruitment
  2024-516026-56-00 3 2017-08-17 Histologically confirmed locally advanced or metastatic solid tumor (S
• A Clinical Phase II, multicenter, Open-label study evaluating iNduction, consolidation and maintenance treatment with Isatuximab (SAR650984) … Ended recruitment
  2024-511791-32-00 4 2017-08-15 Multiple Myeloma
• B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and … Ended recruitment
  2023-505509-18-00 5 2017-07-12 mature aggressive B-cell lymphoma and leukemia in children and adolesc
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) Ended recruitment
  2023-509671-17-00 5 2017-07-12 Breast Cancer
• Long Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis. Ended recruitment
  2023-505699-31-00 5 2017-01-02 Ulcerative Colitis
• A study to decide what is the highest dose of CC-220 to take alone and with other standard of care treatments to assess the side effects, ef … Ended recruitment
  2024-510799-19-00 9 2016-08-09 Multiple Myeloma
• Neoadjuvant L19IL2/L19TNF- Pivotal study Ended recruitment
  2024-515749-40-00 5 2016-02-25 Malignant melanoma of the skin in patients with locally advanced and f
• Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage … Ended recruitment
  2023-509136-25-00 5 2015-07-16 Stage III melanoma (AJCC R0) with histologically confirmed cutaneous m
• Further 2 years of adjuvant imatinib may improve recurrence-free survival (RFS) of patients who are at a high risk of GIST recurrence despit … Ended recruitment
  2024-512243-23-00 5 2014-11-07 gastrointestinal stromal tumor
• Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended recruitment
  2024-511096-15-00 5 2014-08-01 Breast Cancer
• Phase 2a study to assess the efficacy and safety of GIA632 in adult participants with moderate to severe atopic dermatitis Halted
  2025-521503-43-00 4 2026-02-12 Atopic dermatitis
• A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small … Halted
  2023-503298-39-00 5 2024-06-13 Metastatic Non-Small Cell Lung Cancer (mNSCLC)
• To Investigate whether the combination of molidustat and an IDH1 inhibitor (ivosidenib) effectively inhibits leukaemia cells in patients wit … Halted
  2024-514051-15-00 7 2023-07-10 Adult patients with relapsed or refractory IDH1-mutated AML or relapse
• Study of efficacy and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C- muta … Halted
  2024-511708-18-00 4 2022-12-06 Locally advanced or metastatic KRAS G12C-mutated non-small cell lung c
• A phase 1/2 study of subcutaneous blinatumomab administration in adults and adolescents with R/R and MRD+ B-ALL Halted
  2023-506136-32-00 9 2020-10-12 Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (
• An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients with Focal Onset or Primary Generalized Tonic … Ended
  2024-517061-16-01 4 2025-02-27 Focal onset seizures or primary generalized tonic-clonic seizures
• A Phase 2, Dose-Ranging Study of LY4100511 (DC-853) in Adult Participants with Moderate-to-Severe Plaque Psoriasis Ended
  2024-512207-39-00 4 2025-01-30 Plaque Psoriasis
• Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study of Efficacy and Safety of ESK-001 for Moderate to Severe Pl … Ended
  2023-507193-40-00 5 2025-01-16 Moderate to Severe Plaque Psoriasis
• Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and … Ended
  2024-517340-61-00 5 2024-11-19 Patients after curative intent resection of cholangiocarcinoma (intrah
• Multicenter, Prospective, Open-label, Randomized, Crossover Study to Evaluate Pharmacokinetics (PK), Safety, and Tolerability of TAK-881 in … Ended
  2022-502095-23-01 10 2024-09-10 Primary Immunodeficiency Diseases
• “A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis” Ended
  2023-503289-22-00 4 2024-07-05 Relapsing Multiple Sclerosis

Showing 457–480 of 591 trials